Výsledky vyhledávání

OP0024 DIFFERENTIATION BETWEEN IL-6 AND IL-17 PATHWAY INHIBITION IN RELATIONSHIP WITH CLINICAL OUTCOMES IN NON-BIOLOGICAL DMARD-IR AND BIOLOGICAL DMARD-IR PSORIATIC ARTHRITIS PATIENTS TREATED WITH UPADACITINIB IN SELECT-PsA 1 AND SELECT-PsA 2 STUDIES

Autor: F. Cai, T. Sornasse, M. Ruzek, Y. Fang, K. Kato, P. Wung, I. McInnes

Publikováno v: Annals of the Rheumatic Diseases. 81:17-18

BackgroundThe differential contribution of IL-6 and IL-17 pathways to the pathogenesis of psoriatic arthritis (PsA) is not fully understood. Upadacitinib (UPA), an oral JAK inhibitor, was more effective than placebo (PBO) in improving key clinical ma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e88afa2583d2706401978fc87ce04663
https://doi.org/10.1136/annrheumdis-2022-eular.801

Zobrazit plný text záznamu

POS0541 PREDICTORS OF REMISSION IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH UPADACITINIB OR ADALIMUMAB IN THE SELECT-COMPARE PHASE 3 STUDY: CLINICAL STATUS AT WEEK 12, BUT NOT STANDARD LABORATORY MEASURES, PROVIDES THE BEST CURRENT PREDICTOR OF REMISSION AT WEEK 26

Autor: T. Sornasse, F. Cai, F. Hong, S. Anyanwu, I. H. Song, M. Bukhari

Publikováno v: Annals of the Rheumatic Diseases. 81:533.2-534

BackgroundUpadacitinib (UPA, 15 mg QD), an oral JAK1 selective inhibitor, showed greater efficacy compared to adalimumab (ADA, 40 mg EOW) at week 12 in patients with active rheumatoid arthritis (RA) on background methotrexate (MTX) in the SELECT-COMP

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::acacfe73b8ecf8a0e69cc10bb4401016
https://doi.org/10.1136/annrheumdis-2022-eular.2544

Zobrazit plný text záznamu

POS0692 RHEUMATOID ARTHRITIS PATIENTS WHO SWITCHED TREATMENT FROM ADALIMUMAB TO UPADACITINIB DEMONSTRATE A ROBUST REDUCTION OF INFLAMMATION-RELATED BIOMARKERS: PROTEOMICS ANALYSIS FROM THE SELECT-COMPARE PHASE 3 STUDY

Autor: T. Sornasse, F. Cai, H. Camp, I. H. Song, I. Mcinnes

Publikováno v: Annals of the Rheumatic Diseases. 81:625-625

BackgroundUpadacitinib 15 mg QD (UPA), an oral JAK inhibitor, showed greater efficacy compared to adalimumab (ADA) in patients (pts) with active rheumatoid arthritis (RA) on background MTX at wk 12 of the SELECT-COMPARE phase 3 study1. A subset of pt

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::32ece41ebcc5957bb18a1b4b8aa53aff
https://doi.org/10.1136/annrheumdis-2022-eular.2527

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

POS0407 PROTEOMICS ANALYSIS COMPARING THE MODE OF ACTION OF UPADACITINIB BETWEEN NON-BIOLOGIC-DMARD-IR AND BIOLOGIC-DMARD-IR PsA PATIENTS IDENTIFIES DISTINCT PATHOGENIC PATHWAYS IN THE SELECT-PsA 1 AND SELECT-PsA 2 PHASE 3 STUDIES

Autor: K. Kato, Jaclyn K Anderson, Christopher T. Ritchlin, A. Lertratanakul, I.B. McInnes, T. Sornasse

Publikováno v: Annals of the Rheumatic Diseases. 80:433.1-433

Background:Treatment of non-biologic-DMARD-IR1 (DMARD-IR) and biologic-DMARD-IR2 (bio-IR) PsA patients with upadacitinib (UPA) at 15 mg QD, an oral JAK1 selective inhibitor, resulted in significant improvement in signs and symptoms compared to placeb

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7cdeba7b564d3b73cd593dfac798661c
https://doi.org/10.1136/annrheumdis-2021-eular.1652

Zobrazit plný text záznamu

POS0920 TARGETED SERUM PROTEOMIC ANALYSIS FOLLOWING UPADACITINIB TREATMENT IN ANKYLOSING SPONDYLITIS SHOWS ROBUST SUPPRESSION OF INNATE AND ADAPTIVE IMMUNE PATHWAYS WITH TISSUE REPAIR MODULATION

Autor: D. McGonagle, T. Sornasse, I. H. Song, T. Radstake

Publikováno v: Annals of the Rheumatic Diseases. 80:721.1-721

Background:Upadacitinib (UPA), an oral JAK inhibitor selective for JAK1, demonstrated efficacy in patients with active ankylosing spondylitis (AS) with an inadequate response (IR) to nonsteroidal anti-inflammatory drugs (NSAID) therapy in the SELECT-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9f3cd79d2565333a86ebe693f3eb6e07
https://doi.org/10.1136/annrheumdis-2021-eular.1894

Zobrazit plný text záznamu

OP0030 TREATMENT OF NON-BIOLOGIC-DMARD-IR PSA PATIENTS WITH UPADACITINIB OR ADALIMUMAB RESULTS IN THE MODULATION OF DISTINCT FUNCTIONAL PATHWAYS: PROTEOMICS ANALYSIS OF THE SELECT-PSA 1 PHASE 3 STUDY

Autor: T. Sornasse, A. Lertratanakul, I. McInnes, K. Kato, Christopher T. Ritchlin, Jaclyn K Anderson

Publikováno v: Annals of the Rheumatic Diseases. 80:16-16

Background:Treatment of non-biologic-DMARD-IR (DMARD-IR) PsA patients with upadacitinib (UPA) at 15 mg QD, an oral JAK1 selective inhibitor, resulted in improvement in musculoskeletal symptoms, psoriasis, physical function, fatigue, quality of life,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::04520cb29618494edf42ba1335070197
https://doi.org/10.1136/annrheumdis-2021-eular.1462

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

FRI0026 PROTEOMICS ANALYSIS COMPARING THE MODE OF ACTION OF UPADACITINIB AND ADALIMUMAB HEAD TO HEAD IN RA IDENTIFIES NOVEL, DISCRETE EARLY IMMUNE PATHWAY MODULATION IN THE SELECT-COMPARE PHASE 3 STUDY

Autor: T. Sornasse, I.B. McInnes, I. H. Song, T. Radstake

Publikováno v: Annals of the Rheumatic Diseases. 79:585.1-586

Background:Upadacitinib (UPA), an oral JAK1 selective inhibitor, showed greater efficacy compared to adalimumab (ADA) in patients with active rheumatoid arthritis (RA) despite treatment with methotrexate (MTX) in the SELECT-COMPARE phase 3 study1. Th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::855e414d780d3b2ee3bea1fc0055bc9e
https://doi.org/10.1136/annrheumdis-2020-eular.1908

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání